PAR-25-135 NCI K99 eligibility Guide
Updated 8 official sources
Quick Answer: PAR-25-135 is the active NCI K99/R00 Pathway to Independence route for cancer postdocs who need mentored K99 support before moving to an independent R00 phase and are not proposing to lead an independent clinical trial.
Full answer and how we checked it
The October 14, 2026 receipt date has passed; two more follow in 2027 (February 17 and June 15) before NIH retires the current K announcements by July 13, 2027. The decision turns on 7 checks.
Who this is for: Cancer postdocs, physician-scientists, mentors, department chairs, training offices, and sponsored-research teams deciding whether the no-trial NCI K99/R00 is the right route.
Data note: This guide uses NIH PAR-25-135, NIH PAR-25-313, the NCI K99/R00 program page, Grants.gov listing 357259, NIH notices NOT-OD-26-098 and NOT-OD-26-120, and USAspending data, checked again on October 9, 2026.
In this guide
- Source Check
- 7 PAR-25-135 Eligibility Stop Checks
- 5 Source Facts Applicants Should Know
- What NCI Doesn't Tell You
- The 6-Year Clock, Titles, and Prior Awards
- Award Money in Each Phase
- Reference Letters, Mentor Statements, and the R00 Transition
- 6 Evidence Assets That Make This K99/R00 Stronger
- 5 Route Choices Before Drafting
- 6 Bad-Fit Signals
- 21-Day K99/R00 Readiness Plan
- 6 Final Research Checks Before Submission
- 4 Public Decision Questions For Candidates
- 7 Route Checks
- Sources
According to NIH in PAR-25-135 (opens in a new tab), this route helps postdoctoral researchers with clinical or research doctorates move from mentored postdoctoral positions to independent, tenure-track or equivalent faculty positions. NIH also says this NOFO is for candidates whose work does not involve leading an independent clinical trial.
The decision question is not just "Is the candidate strong?" The real question is whether the candidate is still eligible, can justify further mentored development, and can show a distinct R00 research program.
Use this guide with the live NCI K99/R00 clinical trial not allowed program record. Then compare NCI K99 Clinical Trial Required guide, NCI R25 Courses guide, NIH grants complete guide, NIH R01 R21 R03 K awards comparison, NIH K99/R00 pathway guide, NCI payline guide, what is a NOFO, and the Grantsights grant database.
Source Check
Checked October 2026.
According to NIH in PAR-25-135 (opens in a new tab), this NCI K99/R00 route remains active. The October 14, 2026 receipt date has passed, so the next receipt date is February 17, 2027, followed by June 15, 2027, with 5 p.m. local-time submission. The NOFO itself still lists an October 14, 2027 date and an October 15, 2027 expiration, but NIH notice NOT-OD-26-098 (opens in a new tab) (August 12, 2026) says any active NOFO using the current K activity codes will be expired by July 13, 2027. K99 applications due on or after October 12, 2027 move to a new KT1/R00 parent announcement. Candidates who submitted on October 14 should expect review in March 2027, council in May 2027, and a K99 start no earlier than July 2027. NIH says this route is clinical trial not allowed, but candidates may gain experience in a mentor-led clinical trial when they are not leading it.
According to the NCI K99/R00 award page (opens in a new tab), NCI no longer participates in the parent K99/R00 announcements. NCI says applicants must use PAR-25-135 for no-trial applications or PAR-25-313 (opens in a new tab) when the candidate will lead an independent clinical trial. That second option is ending: NOT-OD-26-098 (opens in a new tab) says NIH will no longer support "Independent Clinical Trial Required" K announcements, and K award funds may not pay for conducting a clinical trial. K awardees can still gain trial experience in a trial led by a mentor or co-mentor, and candidates who want to lead a trial as PI must find separate funding.
One change helps February and June 2027 applicants. NIH notice NOT-OD-26-120 (opens in a new tab) (October 5, 2026) says Data Management and Sharing Plans are no longer required for any K award application, effective immediately, and NIH won't treat a missing DMS Plan as noncompliant.
| October 2026 check | Current source read | Applicant action |
|---|---|---|
| Status | Active, but NIH expires current K announcements by July 13, 2027 | Use the NCI-specific announcements for the February 2027 or June 2027 dates |
| Next receipt | February 17, 2027 (October 14, 2026 has passed) | Check whether the candidate clock allows the February or June 2027 cycle |
| Trial boundary | Candidate cannot lead an independent trial | PAR-25-313 covers candidate-led trials only until it expires; future K awards can't fund trial conduct |
| Postdoc window | No more than 6 years at initial or resubmission application | Calculate leave and extension facts before writing |
| NCI routing | Parent K99 is not an NCI path | Do not submit to a parent K99 notice for NCI |
| DMS Plan | Not required for K applications (NOT-OD-26-120 (opens in a new tab)) | Drop the DMS Plan from the 2027 package |
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
7 PAR-25-135 Eligibility Stop Checks
| Stop check | Strong PAR-25-135 signal | Red flag |
|---|---|---|
| Candidate stage | Mentored postdoc, not independent | Faculty or non-mentored research role |
| Experience | No more than 6 years postdoctoral research | Over the limit |
| Trial status | No independent clinical trial | Candidate leads a trial |
| K99 need | Further mentored development is justified | Candidate is already ready |
| Cancer fit | NCI mission is direct | Weak cancer relevance |
| R00 plan | Independent research program is clear | Mentor project continues |
| Award history | No disqualifying PI history | Prior major independent award |
K99 decisions go wrong when teams treat this as a prestige award instead of a timing and independence test.
5 Source Facts Applicants Should Know
According to NIH in PAR-25-135 (opens in a new tab), the activity code is K99/R00, clinical trials are not allowed, and the total project period may not exceed 5 years. NIH states that candidates must have no more than 6 years of postdoctoral research experience at initial application or later resubmission.
According to the NCI K99/R00 award page (opens in a new tab), NCI no longer participates in parent K99/R00 announcements and NCI K99/R00 applications must use PAR-25-135 or PAR-25-313. According to USAspending.gov (opens in a new tab) data, Assistance Listing 93.398 (Cancer Research Manpower) had about $216.8 million in FY2024 grant obligations. That listing covers all NCI training and career awards, not just the K99/R00.
| Fact | Source-backed read |
|---|---|
| Funding number | PAR-25-135 |
| Mechanism | K99/R00 career transition award |
| Clinical trial status | Not allowed |
| Candidate window | No more than 6 years postdoctoral experience |
| Next receipt date | February 17, 2027 (October 14, 2026 has passed) |
| Last receipt date under this NOFO | June 15, 2027 |
| Expiration | By July 13, 2027, per NOT-OD-26-098 (the NOFO still lists October 15, 2027) |
| DMS Plan | No longer required for K applications (NOT-OD-26-120) |
What NCI Doesn't Tell You
Within 21 days, answer 4 practical questions. First, the candidate cannot be too independent. NIH says applications from candidates in independent or non-mentored positions are nonresponsive.
Second, no-trial status does not mean no human work. A candidate may gain experience in a mentor-led clinical trial, but the candidate cannot propose to lead an independent clinical trial under this route.
Third, the R00 plan must separate from the mentor. Don't submit if the independent phase looks like a renamed mentor project.
Fourth, timing matters. A candidate near the 6-year limit needs resubmission math before they build a full application.
The 6-Year Clock, Titles, and Prior Awards
Eligibility is decided by 3 tests before reviewers see the science. The clock counts only research time: NIH says candidates must have no more than 6 years of postdoctoral research experience as of the relevant due date, whether the application is new or a resubmission.
| Eligibility question | What PAR-25-135 (opens in a new tab) says |
|---|---|
| What counts toward 6 years | Only time spent on research; part-time research is prorated |
| What does not count | Parental, medical, military, or other justified leave generally under 12 months, and clinical training with no research |
| Childbirth | NCI approves a one-year extension; send the child's date of birth to an NCI program official |
| Disqualifying titles | Research assistant professor or assistant professor; these applications are withdrawn |
| Disqualifying awards | Prior independent PD/PI on an NIH R01, R03, or R21, an NIH K01, K07, K08, K23, or K25, or another peer-reviewed grant over $100,000 direct costs a year |
| Citizenship | Not required; for a temporary visa holder, the institution documents that the visa covers the K99 phase |
| Effort | At least 9 person-months, or 75% of full-time effort |
Independence timing is the trap. If a candidate takes any faculty or non-mentored research position before the K99 is awarded, NIH issues neither the K99 nor the R00. A candidate interviewing for faculty jobs while the application is pending should talk to NCI program staff first.
Award Money in Each Phase
The two phases are funded very differently, and the R00 budget is a total-cost figure.
| Item | K99 mentored phase | R00 independent phase |
|---|---|---|
| Length | Up to 2 years | Up to 3 years |
| Salary | NCI contributes up to $100,000 a year, plus fringe | Included in the R00 total |
| Research and development costs | Up to $30,000 a year | Included in the R00 total |
| Total cap | Salary plus research costs above | Up to $249,000 a year, including indirect costs |
| Indirect costs | 8% of modified total direct costs | The R00 institution's rate |
| Mentor or administrative salary | Not allowed | Not allowed |
Because the R00 cap includes indirect costs, a candidate moving to an institution with a high indirect rate gets less research money from the same $249,000. That is worth knowing before negotiating a start-up package.
Reference Letters, Mentor Statements, and the R00 Transition
Two parts of the application come from other people, and both can stop it. Reference letters go through the eRA Commons referee link, not Grants.gov, and NIH does not review an application missing its required letters. The primary mentor's statement must cover supervision plans, a commitment to annual progress evaluations, and help with the job search and R00 application. When the candidate gains experience in a mentor-led clinical trial, the mentor must also document that they lead the trial.
The R00 is not automatic. The NCI K99/R00 award page (opens in a new tab) says the candidate must accept a tenure-track, full-time assistant professor position or equivalent, and the new institution submits the R00 application at least 2 months before the planned activation date. NCI also requires the R00 institution to protect 75% research effort, not use R00 funds to offset a normal start-up package, and confirm that the appointment does not depend on the award transferring. NIH says R00 awards generally go only to candidates who accept such a position by the end of the K99 period.
6 Evidence Assets That Make This K99/R00 Stronger
Within 21 days, build 6 evidence assets. Asset 1 is the candidate timeline: doctoral degree, postdoctoral start, leave periods, childbirth extension if relevant, and expected submission dates.
Asset 2 is the independence memo. It should list current title, appointment terms, PI authority, prior awards, and whether the candidate can already apply as an independent investigator.
Asset 3 is the no-trial memo. State whether the project has human participants, whether the candidate leads any trial activity, and whether the work belongs under PAR-25-135 or PAR-25-313. Remember that PAR-25-313 expires by July 13, 2027, and NIH says future K awards won't pay for conducting a trial.
Asset 4 is the mentored-development plan. Include training gaps, mentors, milestones, and why further mentored K99 support is needed.
Asset 5 is the R00 one-pager. It should read like a future lab program with its own question, resources, protected time, and NCI mission fit.
Asset 6 is the route comparison. Compare PAR-25-135 with PAR-25-313, parent K99 paths, K08, K23, R21, and early R01 options.
5 Route Choices Before Drafting
Within 21 days, compare 5 routes.
| Route | Better first read when... | Why |
|---|---|---|
| PAR-25-135 | Candidate does not lead a clinical trial | Route fits |
| PAR-25-313 | Candidate proposes an independent clinical trial and can apply before it expires by July 13, 2027 | Companion route fits for now |
| K08 or K23 | Clinician training needs differ | Other K route may fit |
| R21 or R01 | Candidate is already independent | Career award may be wrong |
| Institutional bridge | Timing or title blocks K99 | Local route may fit |
The strongest application explains why this award, this candidate, and this timing line up.
6 Bad-Fit Signals
First, the candidate is already independent. Second, the candidate exceeds the 6-year postdoctoral window. Third, the candidate will lead an independent clinical trial.
Fourth, the research plan duplicates the mentor's aims. Fifth, the candidate has disqualifying independent PI history. Sixth, the R00 institution plan is vague.
Those stop checks help users avoid a career-award path that can fail before peer review.
21-Day K99/R00 Readiness Plan
Days 1 through 3 should confirm the candidate clock, current title, prior awards, trial status, and deadline. Days 4 through 7 should write the no-trial and independence memos.
Days 8 through 12 should build the training plan and mentor table. Days 13 through 16 should draft the R00 program. Days 17 through 21 should compare PAR-25-135, PAR-25-313, K08/K23, R21/R01, and bridge options.
6 Final Research Checks Before Submission
Within 21 days, finish 6 final research checks. Check 1 is the current NIH notice. Check 2 is the NCI K99 page because NCI now routes applicants through its own K99 announcements. Check 3 is the candidate's postdoctoral clock. Check 4 is no-trial status. Check 5 is mentor overlap. Check 6 is the R00 job-market plan.
You're ready when the candidate can explain why PAR-25-135 is better than the clinical-trial-required path and why the R00 phase will be independent.
4 Public Decision Questions For Candidates
Within 21 days, ask 4 public decision questions. Question 1: "Are you still in a mentored postdoctoral role?" Question 2: "Are you within the 6-year postdoctoral window?" Question 3: "Are you avoiding candidate-led independent clinical trials?" Question 4: "Can the R00 plan stand apart from the mentor's work?"
If the answer to any of these is unclear, talk to NCI program staff before drafting. The answers should show that eligibility, trial status, mentor overlap, and independence are all separate gates.
7 Route Checks
Added June 2, 2026.
Checked on June 2, 2026 against PAR-25-135 (opens in a new tab), the NCI K99 page (opens in a new tab), the Grants.gov listing (opens in a new tab), PAR-25-313 (opens in a new tab), and USASpending.gov (opens in a new tab).
| Check | Public answer |
|---|---|
| Eligibility | Confirm the applicant, institution, and route rules for PAR-25-135 NCI K99 eligibility. |
| Source status | Verify the official listing, notices, due date, and expiration status, including NOT-OD-26-098. |
| Budget | Check award size, cost limits, match, or budget logic when the source provides it. |
| Evidence | Name the data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Stop if the project belongs in a nearby NCI or federal route. |
| Review criteria | Tie the first page to significance, approach, team, environment, and source-specific criteria. |
| Next action | Decide whether to draft for the February or June 2027 date, ask a program contact, redirect, or wait for the KT1/R00 parent announcement. |
Final public checklist
- Confirm whether K99 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open NCI K99 no-trial record
Check PAR-25-135, June and October 2026 receipt dates, 6-year postdoc window, and no-trial route.
Compare trial-required K99
Use when the candidate will lead an independent clinical trial under PAR-25-313.
Compare NIH K awards
Use when K08, K23, or another career route may fit better than NCI K99/R00.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAR-25-135 fund?
It supports NCI K99/R00 career transition awards for postdoctoral researchers who are not proposing to lead an independent clinical trial.
Are clinical trials allowed?
No. PAR-25-135 is clinical trial not allowed, though a candidate may gain experience in a mentor-led clinical trial.
What postdoctoral time limit applies?
Candidates must have no more than 6 years of related postdoctoral research experience at initial application or resubmission.
What is the next 2026 deadline?
The October 14, 2026 receipt date has passed. February 17, 2027 is the next receipt date for new and resubmission applications, followed by June 15, 2027. NIH notice NOT-OD-26-098 says current K announcements, including this one, will expire by July 13, 2027; K99 applications due on or after October 12, 2027 move to a new KT1/R00 parent announcement.
Who should skip this route?
Skip it if the candidate is already independent, will lead an independent clinical trial, or lacks a clear R00 independence plan.
Last updated October 9, 2026. Corrected October 9, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
NCI K99 Clinical Trial Required Guide
PAR-25-313 guide: NCI K99/R00 clinical trial required eligibility, postdoc limits, K99 to R00 transition, salary, and route checks.
PA-25-304: NIH Parent R21 (Clinical Trial Not Allowed)
PA-25-304 is NIH's parent R21 with no clinical trial: $275,000 over 2 years, 21 institutes. Next due Nov 16, 2026 and Feb 16, 2027; expires Jan 8, 2028.
PAR-25-032 NHLBI R34 pilot eligibility Guide
PAR-25-032 NHLBI R34: $450,000 direct over 3 years, new due dates through March 16, 2027, and what 151 past pilots led to.
NINDS U01 Clinical Trial Renewal Guide
PAR-25-149 guide: NINDS U01 clinical trial renewal eligibility, no-new-aims rule, milestone proof, Nov. 5 due date, and route checks.
PAR-24-280 clinical observational R01 eligibility Guide
PAR 24 280 clinical guide: 7 checks for eligibility, source status, budget, evidence, route fit, and review criteria in 2026.
PAR-25-153 NCI Assay Screening R01 Eligibility Guide
NIH PAR-25-153 guide: NCI assay-development and screening R01 eligibility, clinical-trial-not-allowed fit, stages, and review checks.